Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Company inks HAP Technology license agreement with Organon
August 15th, 2005
Genaissance Pharmaceuticals, Inc., (GNSC) announced that it has entered into an agreement with Organon, the human healthcare business unit of Akzo Nobel, under which the companies will apply Genaissance's HAP Technology for pharmacogenetic research in clinical trials, looking at modulation of the hypothalamo-pituitary-adrenal stress axis for the treatment of psychiatric disorders. Pharmacogenetic research is based on the fact that there are large interindividual differences in the response to drugs, be it therapeutic efficacy or unwanted side effects. The goal of the collaboration is to discover genetic markers related to these interindividual differences in drug...
Source: Pharma Business Week (2005-08-15)
|
